Kyle Mikson
Stock Analyst at Canaccord Genuity
(1.78)
# 3,236
Out of 4,962 analysts
86
Total ratings
32.39%
Success rate
-9.48%
Average return
Main Sectors:
Stocks Rated by Kyle Mikson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QTRX Quanterix | Downgrades: Hold | $12 → $5 | $4.67 | +7.07% | 7 | Aug 11, 2025 | |
| ILMN Illumina | Maintains: Hold | $99 → $105 | $99.66 | +5.36% | 12 | Aug 1, 2025 | |
| XGN Exagen | Maintains: Buy | $8 → $11 | $9.85 | +11.68% | 4 | Jul 30, 2025 | |
| GRAL GRAIL | Maintains: Buy | $32 → $43 | $32.93 | +30.60% | 2 | May 14, 2025 | |
| BDSX Biodesix | Maintains: Buy | $2.5 → $1.5 | $0.49 | +206.44% | 4 | May 14, 2025 | |
| TXG 10x Genomics | Maintains: Buy | $18 → $15 | $14.07 | +6.61% | 8 | May 12, 2025 | |
| CSTL Castle Biosciences | Maintains: Buy | $42 → $37 | $20.57 | +79.87% | 4 | May 6, 2025 | |
| GH Guardant Health | Maintains: Buy | $60 → $65 | $61.88 | +5.04% | 7 | May 1, 2025 | |
| RGEN Repligen | Maintains: Hold | $170 → $150 | $121.26 | +23.70% | 3 | Apr 16, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Buy | $3 | $1.32 | +127.27% | 8 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $195 | $162.47 | +20.02% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 | $1.16 | +158.62% | 4 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $1.5 → $1 | $1.14 | -12.28% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $75 | $45.66 | +64.26% | 9 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $2 | $0.69 | +191.72% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $49 | $0.49 | +9,963.41% | 1 | Mar 30, 2021 |
Quanterix
Aug 11, 2025
Downgrades: Hold
Price Target: $12 → $5
Current: $4.67
Upside: +7.07%
Illumina
Aug 1, 2025
Maintains: Hold
Price Target: $99 → $105
Current: $99.66
Upside: +5.36%
Exagen
Jul 30, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $9.85
Upside: +11.68%
GRAIL
May 14, 2025
Maintains: Buy
Price Target: $32 → $43
Current: $32.93
Upside: +30.60%
Biodesix
May 14, 2025
Maintains: Buy
Price Target: $2.5 → $1.5
Current: $0.49
Upside: +206.44%
10x Genomics
May 12, 2025
Maintains: Buy
Price Target: $18 → $15
Current: $14.07
Upside: +6.61%
Castle Biosciences
May 6, 2025
Maintains: Buy
Price Target: $42 → $37
Current: $20.57
Upside: +79.87%
Guardant Health
May 1, 2025
Maintains: Buy
Price Target: $60 → $65
Current: $61.88
Upside: +5.04%
Repligen
Apr 16, 2025
Maintains: Hold
Price Target: $170 → $150
Current: $121.26
Upside: +23.70%
Pacific Biosciences of California
Apr 10, 2025
Maintains: Buy
Price Target: $3
Current: $1.32
Upside: +127.27%
Feb 28, 2025
Maintains: Buy
Price Target: $180 → $195
Current: $162.47
Upside: +20.02%
Nov 14, 2024
Maintains: Buy
Price Target: $3
Current: $1.16
Upside: +158.62%
Nov 13, 2024
Maintains: Hold
Price Target: $1.5 → $1
Current: $1.14
Upside: -12.28%
Nov 6, 2024
Maintains: Buy
Price Target: $95 → $75
Current: $45.66
Upside: +64.26%
Aug 16, 2023
Maintains: Overweight
Price Target: $3 → $2
Current: $0.69
Upside: +191.72%
Mar 30, 2021
Initiates: Overweight
Price Target: $49
Current: $0.49
Upside: +9,963.41%